Possible scenario
Obesity Market Reprices
18% Chance
The headline result changes relative valuations across obesity-drug developers rather than only Roche. Investors reassess which companies have differentiated assets, manufacturing capacity, and credible partnering leverage in a crowded market.
Secondary impacts
- Healthcare +0.3%
Tickers
- VKTX-0.5%
- LLY+0.3%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.